Tumor induced osteomalacia
Authors:
Lenka Filipová 1; Ivica Lazúrová 2
Authors place of work:
Endokrinologická ambulancia, Nemocnica Agel Košice Šaca, a. s.
1; IK UNLP a LF UPJŠ Košice
2
Published in the journal:
Vnitř Lék 2021; 67(E-8): 19-22
Category:
Review Articles
Summary
Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome typically caused by small endocrine tumors that secrete fibroblast growth factor 23(FGF23). TIO is clinically characterized by progressive muskuloskeletal pain, fatigue, proximal muscle weakness, and multiple fractures that lead to long-term disability. Due to the non-specific symptoms of the disease, it may take several years for them to be properly diagnosed and treated, so it is important to better inform about this rare paraneoplastic syndrome.
Keywords:
FGF23 – hypophosphataemia – tumor induced osteomalacia
Zdroje
1. Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor‑Induced Osteomalacia. Calcif Tissue Int. 2021 Jan;108(1):128-142.
2. Li X, Jiang Y, Huo L, et al. Nonremission and Recurrent Tumor‑Induced Osteomalacia: A Retrospective Study. J Bone Miner Res. 2020;35(3):469-477.
3. Agaimy A, Michal M, Chiosea S, Petersson F, Hadravsky L, Kristiansen G, et al. Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. The American Journal of Surgical Pathology. 2017;41(10):1371–1380.
4. Huang X, Jiang Y, Xia W. FGF23 and Phosphate Wasting Disorders. Bone Res. 2013 Jun 28;1(2):120-32.
5. Yin Z, Du J, Yu F, Xia W. Tumor‑induced osteomalacia. Osteoporos Sarcopenia. 2018;4(4):119-127.
6. Feng J, Jiang Y, Wang O, Li M, Xing X, Huo L, Li F, Yu W, Zhong DR, Jin J, Liu Y, Qi F, Lv W, Zhou L, Meng XW, Xia WB. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017 Jul 28;64(7):675-683.
7. Tiefenbach, M, Scheel, M, Maier A et al. Osteomalazie - Klinik, Diagnostik und Therapie. Z Rheumatol 2018;77, 703–718
8. Tesár TO. An expanding family of hypophoshatemic syndromes. J Bone Miner Metab 2012; 30 : 1–9.
9. Svačina, Š. et al. Poruchy metabolizmu a výživy. Praha:Galen 2010.106-109. ISBN 978-80-7262-676-2.
10. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor‑induced osteomalacia. Endocr Relat Cancer. 2011;18(3):R53-77.
11. Zhang J., Zhu Z., Zhong D., Dang Y., Xing H., Du Y. 68Ga DOTATATE PET/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin Nucl Med. 2015;40:642–646.
12. Jiang Y, Hou G, Cheng W. Performance of 68Ga‑DOTA‑SST PET/CT, octreoscan SPECT/ CT and 18 F‑FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta‑analysis. Nucl Med Commun. 2020 Apr;41(4):370-376.
13. Athonvarangkul D, Insogna KL. New Therapies for Hypophosphatemia‑Related to FGF23 Excess. Calcif Tissue Int. 2021 Jan;108(1):143-157.
14. Padidela R, Nilsson O, Makitie O, Beck‑Nielsen S, Ariceta G, Schnabel D, Brandi ML, Boot A, Levtchenko E, Smyth M, Jandhyala R, Mughal Z. The international X‑linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet J Rare, DiS. 2020 Jun 30;15(1):172.
15. Song K, Yan Q, Yang Y, et al. Fanconi syndrome induced by adefovir dipivoxil: a case report and clinical review. J Int Med Res. 2020;48(10):300060520954713.
16. Gou M, Ma Z. Osteomalacia, renal Fanconi syndrome, and bone tumor. J Int Med Res. 2018;46(8):3487-3490.
17. Minisola S, Peacock M, Fukumoto S, et al. Tumour‑induced osteomalacia. Nat Rev Dis Primers. 2017;3:17044.
18. Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, Gafni RI, Bhattacharyya N, Boyce AM, El‑Maouche D, Crespo DO, Sherry R, Chang R, Wodajo FM, Kletter GB, Dwyer A, Collins MT. Tumor localization and biochemical response to cure in tumor‑induced osteomalacia. J Bone Miner Res. 2013 Jun;28(6):1386-98.
19. Piemonte S, Romagnoli E, Cipriani C, De Lucia F, Pilotto R, Diacinti D, Pepe J, Minisola S. Six‑year follow‑up of a characteristic osteolytic lesion in a patient with tumor‑induced osteomalacia. Eur J Endocrinol. 2013 Nov 29;170(1):K1-4.
20. Mishra SK, Kuchay MS, Sen IB, Garg A, Baijal SS, Mithal A. Successful Management Of Tumor‑Induced Osteomalacia with Radiofrequency Ablation: A Case Series. JBMR Plus. 2019 Feb 28;3(7):e10178.
21. Dahir, K., Zanchetta, M. B., Stanciu, I., Robinson, C., Lee, J. Y., Dhaliwal, R., Charles, J., Civitelli, R., Roberts, M. S., Krolczyk, S., & Weber, T. Diagnosis and Management of Tumor‑induced Osteomalacia: Perspectives From Clinical Experience. Journal of the Endocrine Society, 1021;5(9), bvab099.
22. Jan De Beur S, Miller P, Weber T, et al. Burosumab improves the biochemical, skeletal, and clinical symptoms of tumor‑induced osteomalacia syndrome. J Endocr Soc. 2019;3(Suppl_1):OR13-1.
23. Imanishi Y, Ito N, Rhee Y, et al. Interim analysis of a phase 2 open‑label trial assessing burosumab efficacy and safety in patients with tumor‑induced osteomalacia. J Bone Miner Res. 2021;36(2):262-270.
24. Hartley IR, Miller CB, Papadakis GZ, et al. Targeted FGFR blockade for the treatment of tumor‑induced osteomalacia. N Engl J Med. 2020;383(14):1387-1389.
25. Cundy T, Que L, Hassan IM, Hughes L. Bisphosphonate‑Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome. JBMR Plus. 2020 Jun 5;4(8):e10374.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2021 Číslo E-8
Najčítanejšie v tomto čísle
- Th1, Th2 and Th17 lymphocytes in autoimmune thyreopathies
- Tumor induced osteomalacia
- Long‑term mechanical circulatory support for chronic heart failure – real life practice
- Lethal alcohol intoxications cases: thinking about the causes